NCT04750954View on ClinicalTrials.gov

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 22, 2021

Primary Completion Date

October 25, 2025

Study Completion Date

October 25, 2025

Conditions
Neuroendocrine Neoplasm
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Lutetium Lu 177 Dotatate

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Peposertib

Given PO

Trial Locations (5)

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

91010

City of Hope Comprehensive Cancer Center, Duarte

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH